ClinicalTrials.gg
CompletedNCT01940341Updated Sep 25, 2023Results posted

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

A Phase 3 interventional study of TAF and TDF in HBeAg-negative Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 105 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-25.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Hepatitis by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Hepatitis · Gilead Sciences.

Enrollment
5th of 23
426 · median 155
Started
2013
with 7 others
Phase 3
9 of 25
none open now
Registered
20th of 25
by date

Among the 25 studies in Hepatitis by Gilead Sciences, this one is the 5th largest by enrollment of the 23 interventional ones that give a count, is one of 8 that started in 2013, is one of 9 in phase 3, and was the 20th registered.

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

None of the 25 studies in Hepatitis by Gilead Sciences is open now. The open studies under Hepatitis, anywhere →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Hepatitis by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection.

Read the detailed description

Study GS-US-320-0108 is a multi-center clinical trial, planned to enroll participants in multiple countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study before China was able to participate. Therefore, details for the China cohort was registered separately (NCT02836236) on ClinicalTrials.gov as the China cohort will not be part of the main study analysis.

03

Conditions studied

  • HBeAg-negative Chronic Hepatitis B

Browse trials for

Keywords

  • Hepatitis
  • Tenofovir
  • Viread
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures.
  • Adult males and non-pregnant, non-lactating females.
  • Documented evidence of chronic infection.
  • Hepatitis e antigen (HBeAg)-negative, chronic hepatitis B with all of the following:

    • HBeAg-negative and hepatitis B e antibody (HBeAb) positive at screening.
    • Screening HBV DNA ≥ 2 x 10\^4 IU/mL.
    • Screening serum (ALT) level > 60 U/L (males) or > 38 U/L (females) and ≤ 10 x the (ULN).
  • Treatment-naive participants (defined as \< 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue), OR treatment-experienced participants (defined as participants meeting all entry criteria [including HBV DNA and serum ALT criteria] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue).
  • Previous treatment with interferon (pegylated or non pegylated) must have ended at least 6 months prior to Baseline.
  • Adequate renal function.
  • Normal (ECG).

Key Exclusion Criteria:

  • Females who are breastfeeding.
  • Males and females of who are unwilling to use an "effective", protocol-specified method(s) of during the study.
  • Co-infection with virus, (HIV), or hepatitis D virus.
  • Evidence of hepatocellular carcinoma.
  • Any history of, or current evidence of, clinical hepatic decompensation.
  • Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) > 10 x ULN
  • Received solid organ or bone marrow transplant.
  • History of within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible.
  • Currently receiving therapy with immunomodulators (eg, ), agents, nephrotoxic agents, or agents capable of modifying renal excretion.
  • Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known to study drugs, metabolites, or formulation .
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance.
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
426 participants (actual)

Study arms

  • Experimental
    TAF 25 mg

    TAF + TDF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).

    Drug: TAF · Drug: TDF Placebo

  • Active comparator
    TDF 300 mg

    TDF + TAF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).

    Drug: TDF · Drug: TAF Placebo

  • Experimental
    Open-label TAF

    All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study. After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment.

    Drug: TAF

Interventions

  • DrugTAF

    25 mg tablet administered orally once daily

    Also known as: Vemlidy®, GS-7340

  • DrugTDF

    300 mg tablet administered orally once daily

    Also known as: Viread®

  • DrugTAF Placebo

    Tablet administered orally once daily

  • DrugTDF Placebo

    Tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL

    The primary efficacy endpoint was determined by the achievement of HBV DNA \< 29 IU/mL at Week 48.

    Time frame: Week 48

Secondary outcomes

  1. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Time frame: Baseline, Week 48

  2. Percent Change From Baseline in Spine BMD at Week 48

    Time frame: Baseline, Week 48

  3. Change From Baseline in Serum Creatinine at Week 48

    Time frame: Baseline, Week 48

Other outcomes

  1. Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.

    Time frame: Up to 48 weeks

07

Results

Posted Mar 30, 2017

Participant flow

Participants were enrolled at study sites in East Asia, Europe, North America, Australia, India, and New Zealand.

Period 1: Double-blind Phase
Participant flow — Period 1: Double-blind Phase
MilestoneTAF 25 mgTDF 300 mgTAF 25 mg to TAF 25 mgTDF 300 mg to TAF 25 mg
Started28514100
Completed26112900
Not completed241200
Withdrew: Withdrew consent7400
Withdrew: Lost to follow-up8100
Withdrew: Adverse event4200
Withdrew: Investigator's discretion3100
Withdrew: Non-compliance with study drug1100
Withdrew: Death0100
Withdrew: Pregnancy0100
Withdrew: Protocol specified criteria for withdrawal1000
Withdrew: Randomized but never treated0100
Period 2: Open-Label TAF Extension Phase
Participant flow — Period 2: Open-Label TAF Extension Phase
MilestoneTAF 25 mgTDF 300 mgTAF 25 mg to TAF 25 mgTDF 300 mg to TAF 25 mg
Started00261129
Completed00227118
Not completed003411
Withdrew: Withdrew consent00174
Withdrew: Investigator's discretion0034
Withdrew: Lost to follow-up0060
Withdrew: Protocol specified criteria for withdrawal0031
Withdrew: Adverse event0020
Withdrew: Death0010
Withdrew: Hbsag seroconversion0010
Withdrew: Non-compliance with study drug0001
Withdrew: Pregnancy0001
Withdrew: Progressive disease0010

Outcome measures

PrimaryPercentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL

The primary efficacy endpoint was determined by the achievement of HBV DNA \< 29 IU/mL at Week 48.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL
Percentage of participantsTAF 25 mgTDF 300 mg
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL94.092.9
Statistical analysis
  • TAF 25 mg vs TDF 300 mg · Difference in proportions: 1.8 · 95% CI -3.6 to 7.2Difference in the proportion between treatment groups and its 95% CI were calculated based on the Mantel-Haenszel (MH) proportions adjusted by baseline HBV DNA categories and oral antiviral treatment status strata.
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percentage changeTAF 25 mgTDF 300 mg
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48-0.288 ± 2.1448-2.156 ± 2.1672
SecondaryPercent Change From Baseline in Spine BMD at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine BMD at Week 48
percentage changeTAF 25 mgTDF 300 mg
Percent Change From Baseline in Spine BMD at Week 48-0.876 ± 2.8558-2.514 ± 3.3558
SecondaryChange From Baseline in Serum Creatinine at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 48
mg/dLTAF 25 mgTDF 300 mg
Change From Baseline in Serum Creatinine at Week 480.01 ± 0.0910.02 ± 0.103
Other pre-specifiedPercentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.

Time frame:
Up to 48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48
percentage of participantsTAF 25 mgTDF 300 mg
Grade 118.116.4
Grade 21.12.1
Grade 300

Adverse events

Collected over All-Cause Mortality: Randomization up to approximately 427.6 weeks Adverse Events: First dose date up to Week 384. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Phase: TAF 25 mg0/285 (0%)26/285 (9.1%)178/285 (62.5%)
Double-blind Phase: TDF 300 mg2/141 (1.4%)17/140 (12.1%)89/140 (63.6%)
Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg1/261 (0.4%)38/261 (14.6%)112/261 (42.9%)
Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg0/129 (0%)17/129 (13.2%)55/129 (42.6%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventDouble-blind Phase: TAF 25 mgDouble-blind Phase: TDF 300 mgOpen-label TAF Extension Phase: TAF 25 mg to TAF 25 mgOpen-label TAF Extension Phase: TDF 300 mg to TAF 25 mg
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2854/1406/2613/129
Abdominal pain upperGastrointestinal disorders0/2850/1400/2612/129
PneumoniaInfections and infestations1/2851/1400/2612/129
CellulitisInfections and infestations0/2852/1400/2611/129
Calculus urinaryRenal and urinary disorders0/2852/1400/2610/129
Coronary artery diseaseCardiac disorders0/2850/1402/2611/129
PalpitationsCardiac disorders0/2850/1400/2611/129
Abdominal painGastrointestinal disorders0/2850/1400/2611/129
Chest painGeneral disorders0/2850/1400/2611/129
PyrexiaGeneral disorders0/2850/1400/2611/129
Most frequent other events
Showing 10 of 18
Most frequent other events
EventDouble-blind Phase: TAF 25 mgDouble-blind Phase: TDF 300 mgOpen-label TAF Extension Phase: TAF 25 mg to TAF 25 mgOpen-label TAF Extension Phase: TDF 300 mg to TAF 25 mg
HeadacheNervous system disorders53/28515/14027/26110/129
NasopharyngitisInfections and infestations40/28519/14019/26110/129
Upper respiratory tract infectionInfections and infestations38/28516/14023/26110/129
ArthralgiaMusculoskeletal and connective tissue disorders30/28517/14016/2618/129
CoughRespiratory, thoracic and mediastinal disorders25/28512/14013/2618/129
HypertensionVascular disorders8/2859/14015/26111/129
Back painMusculoskeletal and connective tissue disorders19/2857/14013/26110/129
NauseaGastrointestinal disorders18/28510/1405/2611/129
FatigueGeneral disorders17/28510/1405/2614/129
InfluenzaInfections and infestations18/2859/14013/2611/129

Baseline characteristics

Safety Analysis Set: Participants who received at least 1 dose of study drugs.

Age, Categorical
Age, Categorical(Participants)TAF 25 mgTDF 300 mgTotal
<=18 years000
Between 18 and 65 years276136412
>=65 years9413
Age, Continuous
Age, Continuous(years)TAF 25 mgTDF 300 mgTotal
Mean45 ± 11.648 ± 10.446 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)TAF 25 mgTDF 300 mgTotal
Female11254166
Male17386259
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAF 25 mgTDF 300 mgTotal
Hispanic or Latino202
Not Hispanic or Latino279140419
Unknown or Not Reported404
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TAF 25 mgTDF 300 mgTotal
Race — Asian205101306
Race — White7135106
Race — Black or African American538
Race — Other or More Than One Race213
Race — Native Hawaiian or Other Pacific Islander202
Region of Enrollment
Region of Enrollment(Participants)TAF 25 mgTDF 300 mgTotal
Hong Kong412869
Canada291746
South Korea301545
Taiwan221537
United States241337
Russia221335
India26733
Japan21627
Romania13821
Poland12618
Turkey10414
New Zealand10212
Australia9110
Italy639
United Kingdom516
France213
Spain303
IL28b Status
IL28b Status(Participants)TAF 25 mgTDF 300 mgTotal
CC209106315
CT652388
TT10919
Missing123
HBV DNA
HBV DNA(Log10 IU/mL)TAF 25 mgTDF 300 mgTotal
Mean5.7 ± 1.345.8 ± 1.325.8 ± 1.33

3 further baseline measures are reported on the registry.

08

Study locations

105 sites
  • Asian Pacific Liver Center
    Los Angeles, California 90020, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Huntington Medical Research Institutes
    Pasadena, California 91105, United States
  • Research and Education, Inc.
    San Diego, California 92105, United States
  • University California San Francisco (UCSF)
    San Francisco, California 94110, United States
  • Silicon Valley Research Institute
    San Jose, California 95128, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • ID Care
    Hillsborough, New Jersey 08844, United States
  • Sing Chan Private Practice
    Flushing, New York 11354, United States
  • New Discovery, LLC
    Flushing, New York 11355, United States
  • Xiaoli Ma, PC
    Philadelphia, Pennsylvania 19107, United States
  • Hunter Holmes McGuire VA DVMC
    Richmond, Virginia 23249, United States
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • St. Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Zeidler Ledcor Centre Division of Gastroenterology
    Edmonton, Alberta T6G 2X8, Canada
  • Liver and Intestinal Research Centre
    Vancouver, British Columbia V5Z 1H3, Canada
  • Gordon and Leslie Diamond Health Care Centre
    Vancouver, British Columbia V5Z 1M9, Canada
  • Dr. John Farley Inc.
    Vancouver, British Columbia V6A 4B6, Canada
  • Vancouver Infectious Disease Research and Care Centre
    Vancouver, British Columbia V6Z 2C7, Canada
  • Gastrointestinal Research Institute (GIRI)
    Vancouver, British Columbia V6Z 2K5, Canada
  • University of Manitoba
    Winnipeg, Manitoba R3E 3P4, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Inspiration Research Limited
    Toronto, Ontario M5T 2S8, Canada
  • Toronto Liver Centre
    Toronto, Ontario M6H 3M1, Canada
  • Hôpital de la Croix Rousse
    Lyon cedex 04, 69317, France
  • Hopital Civil de Strasbourg- CHU Service
    Strasbourg, 67000, France
  • Queen Mary Hospital
    Hong Kong, Hong Kong SAR, Hong Kong
  • Princess Margaret Hospital
    Kwai Chung, Hong Kong
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Alice Ho Miu Ling Nethersole Hospital
    Tai Po, Hong Kong
  • Global Hospitals
    Hyderabad, Andhra Pradesh 500004, India
  • Centre for Liver Research & Diagnostic, Deccan College of Medical Sciences and Allied Hospitals
    Hyderabad, Andhra Pradesh 500058, India
  • All India Institute of Medical Sciences
    New Delhi, Delhi 110029, India
  • Nirmal Hospital
    Surat, Gujarat 395002, India
  • Seth GS Medical College and KEM Hospital
    Mumbai, Maharastra 400012, India
  • Global Hospital Super Specialty & Transplant Centre
    Parel, Mumbai 400 012, India
  • S. R Kalla Memorial Gastro & General Hospital
    Jaipur, Rajasthan 302001, India
  • Institute of Post Graduate Medical Education And Research
    Kolkata, West Bengal 700020, India
  • Postgraduate Institute of Medical Education and Research
    Chandigarh, 160012, India
  • Institute of Liver and Biliary Sciences
    New Delhi, 110070, India
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Foggia 71013, Italy
  • Azienda Ospedaliera S. Orsola - Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliero Universitaria Ospedali
    Foggia, 71122, Italy
  • Azienda Ospedaliero- Universitaria Pisana
    Pisa, 56124, Italy
  • Kurume University Hospital
    Kurume-shi, Fukuoka-ken 830-0011, Japan
  • Kyushu University Hospital Fukuoka
    Fukuoka, Fukuoka-shi 812-8582, Japan
  • National Hospital Organization Nagasaki Medical Center
    Omura-shi, Nagasaki 856-8562, Japan
  • Osaka University Hospital
    Suita, Osaka 565-0871, Japan
  • Shin-Kokura Hospital
    Kitakyushu, 803-8505, Japan
  • Kobe City Medical Center General Hospital
    Kobe, 650-0047, Japan
  • Japan Red Cross Musashino Hospital
    Musashino, 180-8610, Japan
  • The Hospital of Hyogo College of Medicine
    Nishinomiya, 663-8501, Japan
  • Osaka Red Cross Hospital
    Osaka, 543-8555, Japan
  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
  • Medical Hospital of Tokyo Medical and Dental University
    Tokyo, 113-8519, Japan
  • Pusan National University Yangsan Hospital
    Yangsan, Gyeongsangnam-do 50612, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, 42601, Korea, Republic of
  • Yonsei University, Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, 06273, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul Saint Mary Hospital
    Seoul, 06591, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, 06973, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
  • Auckland Clinical Studies Limited
    Auckland, 1010, New Zealand
  • Uniwersytecki Szpital Kliniczny w Bialymstoku Klinika
    Bialystok, 15-540, Poland
  • Szpital Specjalistyczny w Chorzowie Oddział
    Chorzow, 41-500, Poland
  • SPZOZ, Wojewódzki Specjalistyczny Szpital
    Lodz, 91-347, Poland
  • Centrum Badan Klinicznych - Przychodnia Badan
    Wroclaw, 50-349, Poland
  • Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"
    Bucharest, Bucuresti 021105, Romania
  • Centrul Medical de Diagnostic si Tratament "Dr. Victor Babes"
    Bucuresti, 030303, Romania
  • Institutul National de Boli Infectioase Prof.Dr. Matei Bals
    Bucuresti, 21105, Romania
  • Spitatul Clinic de Boli Infectioase Constanta
    Constanta, 900708, Romania
  • Gastromedica SRL
    Iasi, 700506, Romania
  • Infection Center LLC Building 20, MSH #163 Territory Koltsovo
    Koltsovo, Novosibirsk 630559, Russian Federation
  • 1st Moscow State Medical University University Clinical Hospital #3
    Moscow, 119991, Russian Federation
  • Limited Liability Company "Modern Medicine Clinic"
    Moscow, 121293, Russian Federation
  • Infectious Clinical Hospital #1 of Moscow Healthcare Department
    Moscow, 125367, Russian Federation
  • Novosibirsk State Medical University
    Novosibirsk, 630084, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • Scientific Research Institute of Clinical Immunology
    Novosibirsk, 630091, Russian Federation
  • Clinical Infectious Hospital named after S.P.Botkin
    Saint-Petersburg, 191167, Russian Federation
  • Kirov Medical Military Academy
    Saint-Petersburg, 194044, Russian Federation
  • Research Institute of Influenza
    Saint-Petersburg, 197376, Russian Federation
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hualien Tzu Chi Hospital
    Hualien City, 970, Taiwan
  • Kaohsiung Medical University Hospital
    Kaohsiung, 807, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Dicle University Medical Faculty Department of Infectious Diseases
    Diyarbakir, Diyarbakri 21280, Turkey
  • Ankara Üniversitesi Gastroenteroloji Bilim Dalı Cebeci
    Ankara, 06590, Turkey
  • Uludag Üniversitesi Tıp Fakültesi Gastroenteroloji
    Bursa, 16059, Turkey

Showing the first 100 of 105 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01064-18. doi: 10.1128/AAC.01064-18. Print 2018 Oct. PubMed 30038044 ↗
  • Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL. Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. Clin Gastroenterol Hepatol. 2018 Jun 20:S1542-3565(18)30633-5. doi: 10.1016/j.cgh.2018.06.023. Online ahead of print. PubMed 29933096 ↗
  • Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Celen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17. PubMed 29756595 ↗
  • Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Erratum In: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2. doi: 10.1016/S2468-1253(16)30128-5. PubMed 28404092 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Sep 2015, 24 months.

Results were first posted in Mar 2017, 1 year 6 months after primary completion. A results delay was requested in Aug 2016.

Of 23 phase 3 interventional studies under Hepatitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2013
First posted
Sep 12, 2013
StartActual
Sep 12, 2013
Primary completionActual
Sep 30, 2015
CompletionActual
Aug 31, 2022
Results delay requested
Aug 23, 2016
Results first posted
Mar 30, 2017
Last update
Sep 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01940341
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 12, 2013
Start date
Sep 12, 2013
Primary completion
Sep 30, 2015
Completion
Aug 31, 2022
Results posted
Mar 30, 2017
Last update
Sep 25, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion